CD8A and acute myeloid leukemia: Based on our longstanding expertise with clinical tools using mRNA-modified dendritic cell (DC) vaccines in acute myeloid leukemia (AML) patients (12, 13), we adapted our mRNA electroporation protocol to human resting CD8+ T cells for rapid and efficient transient TCR expression (14, 15, 16, 17).